Phase II trial shows potential of antidiabetic drug for NASH
22 Dec 2020
byAudrey Abella
A greater proportion of individuals with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis had NASH resolution with subcutaneous semaglutide, a GLP-1* receptor agonist approved for the treatment of type 2 diabetes (T2D), a phase II study has shown.
